Immunocore Holdings: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
I'm PortAI, I can summarize articles.
Analyst Patrick Trucchio from H.C. Wainwright has reiterated a Buy rating for Immunocore Holdings, maintaining a price target of $100. The strong Q3 performance, particularly from KIMMTRAK, and strategic advancements in clinical trials support this rating. Immunocore's solid financial position enhances its growth potential. Oppenheimer also supports a Buy rating with a price target of $86.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments